# Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome

> **NCT02670525** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 338 (actual)

## Conditions studied

- Recurrent, Refractory, or High Risk Leukemias
- Matched Targeted Therapy

## Interventions

- **GENETIC:** Leukemia Profiling

## Key facts

- **NCT ID:** NCT02670525
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-08-17
- **Primary completion:** 2022-05-16
- **Final completion:** 2028-01-31
- **Target enrollment:** 338 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02670525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02670525, "Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02670525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*